Expression of αv-integrins in uterine serous papillary carcinomas; Implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist antiYαV-integrin antibody

International Journal of Gynecological Cancer

Volumn 21, Issue 6, 2011, Pages 1084-1090

  Bellone, Marta ^a   Cocco, Emiliano ^a   Varughese, Joyce ^a   Bellone, Stefania ^a   Todeschini, Paola ^a   El Sahwi, Karim ^a   Carrara, Luisa ^b   Guzzo, Federica ^a   Schwartz, Peter E ^a   Rutherford, Thomas J ^a   Pecorelli, Sergio ^b   Marshall, Deborah J ^c   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

^c Ortho Biotech Oncology Research and Development   (United States)

Author keywords

V integrin; CNTO 95; Intetumumab; Uterine serous papillary carcinoma

Indexed keywords

ALPHAVBETA5 INTEGRIN; ALPHAVBETA6 INTEGRIN; CD51 ANTIGEN; INTETUMUMAB; POLYCARBONATE; VITRONECTIN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER RESISTANCE; CANCER STAGING; CELL ADHESION; CELL ASSAY; CELL LINE; CELL MIGRATION; CELL SURFACE; CHANNEL GATING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE SEROUS PAPILLARY CARCINOMA; UTERUS CARCINOMA;

AGED; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; CYSTADENOCARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; FEMALE; FLOW CYTOMETRY; HUMANS; INTEGRIN ALPHAV; MIDDLE AGED; MOLECULAR TARGETED THERAPY; UTERINE NEOPLASMS;

EID: 83055165659     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182187324     Document Type: Article

References (21)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistic, 2010. CA Cancer J Clin. 2010;60:277Y300.
2. Clement PB, Young RH. Endometrioid carcinoma of the uterine corpus: a review of its pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol. 2002;9:145Y184.
3. Fadare O, Zheng W. Insight into endometrial serous carcinogenesis and progression. Int J Clin Exp Pathol. 2009;2:411Y432.
4. Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control. 2009;16:8Y13.
5. Kurman RJ, McConnell TG. Precursors of endometrial and ovarian carcinoma. Virchows Arch. 2010;456:1Y12.
6. Nemeth JA, Nakada MT, Trikha M, et al. Alpha-v integrins as therapeutic targets in oncology. Cancer Invest. 2007;25:632Y646. (Pubitemid 350135743)
7. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002;110:673Y687. (Pubitemid 35283958)
8. Cox D, Brennan M, Moran N. Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov. 2010;9:804Y820.
9. Rathinam R, Alahari SK. Important role of integrins in the cancer biology. Cancer Metastasis Rev. 2010;29:223Y237.
10. Zhang Y, Lu H, Dazin P, et al. Squamous cell carcinoma cell aggregates escape suspension-induced, p53-mediated anoikis. Fibronectin and integrin >v integrin mediate survival signals through focal adhesion kinase. J Biol Chem. 2004;279: 48342Y48349. (Pubitemid 39540990)
11. Choi DS, Kim H-J, Yoon J-H, et al. Endometrial cancer invasion depends on cancer-derived tumor necrosis factor-> and stromal derived hepatocyte growth factor. Int J Cancer. 2009;124:2528Y2538.
12. Hecht JL, Dolinski BM, Gardner HA, et al. Overexpression of the >vA6 integrin in endometrial cancer. Appl Immunohistochem Mol Morphol. 2008;16:543Y547.
13. Trikha M, Zhou Z, Nemeth JA, et al. CNTO 95, a fully human monoclonal antibody that inhibits >v integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer. 2004;110:326Y335. (Pubitemid 38649882)
14. Ning S, Tian J, Marshall DJ, et al. Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res. 2010;70: 7591Y7599.
15. Martin PL, Jiao Q, Cornacoff J, et al. Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti->v integrin monoclonal antibody, despite widespread tissue binding. Clin Cancer Res. 2005;11: 6959Y6965. (Pubitemid 41428754)
16. Chen Q, Manning CD, Millar H, et al. CNTO 95, a fully human anti >v integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells. Clin Exp Metastasis. 2008;25:139Y148.
17. Mullamitha SA, Ton NC, Parker GJM, et al. Phase I evaluation of a fully human anti->v integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors. Clin Cancer Res. 2007;13:2128Y2135. (Pubitemid 46649882)
18. Chu FM, Picus J, Fracasso PM, et al. A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human >v integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer. Invest New Drugs. 2010;[Epub ahead of print].
19. Bellone S, Siegel ER, Cocco E, et al. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer. Int J Gynecol Cancer. 2009;19:860Y866.
20. El-Sahwi K, Bellone S, Cocco E, et al. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201). Mol Cancer Ther. 2010;9:57Y66.
21. Tucker GC. Integrins: molecular targets in cancer therapy. Curr Oncol Rep. 2006;8:96Y103.